Skip to content

Biogen BIIB Price / book

Price / book at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×
Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Royalty Pharma logo
Royalty PharmaRPRX
2.1×+0.7×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Amgen logo
AmgenAMGN
20.6×-6.3×
Incyte logo
IncyteINCY
3.3×+0.1×

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Net income$319.5M+32.9%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$29.33B+34.3%
Enterprise value$32.51B+34.9%
P/E20.6×+5.9×
P/S+0.7×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%
Net margin14.3%-0.8pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Calculated from Biogen’s reported figures.

Based on the most recent quarter.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's price / book?
Biogen (BIIB) reported price / book of 1.4× in Q1 2026.
How has Biogen's price / book changed year-over-year?
Biogen's price / book increased by 22.3% year-over-year, from 1.2× to 1.4×.
What is the long-term trend for Biogen's price / book?
Over 4 years (2021 to 2025), Biogen's price / book has grown at a -25.9% compound annual growth rate (CAGR), from 15.8× to 4.8×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.